Advertisement

hautnah dermatologie

, Volume 34, Issue 6, pp 42–46 | Cite as

Psoriasis vulgaris

Sicherheit und unerwünschte Wirkungen der neuesten Biologika

  • Peter Weisenseel
  • Marian Anderko
Zertifizierte Fortbildung
  • 148 Downloads

Zusammenfassung

Die Nebenwirkungen von TNFα-Inhibitoren sind durch ihren weltweiten Einsatz über viele Jahre in diversen Indikationen den Anwendern und Fachgruppen gut bekannt. Möglichen unerwünschten Wirkungen der neuen IL-17- und IL-23-Inhibitoren hingegen sind noch nicht so vertraut.

Literatur

  1. 1.
    Nast A et al. Methods report: Update of the German S3 guideline for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges. 2018; 645–70Google Scholar
  2. 2.
    Langley RG et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014; 371: 326–38CrossRefGoogle Scholar
  3. 3.
    Fitch E et al. Pathophysiology of Psoriasis: Recent Advances on IL-23 and Th17 Cytokines. Curr Rheumatol Rep. 2007; 9: 461–7CrossRefGoogle Scholar
  4. 4.
    Murphy CA et al. Divergent pro- and antiin-flammatory roles for IL-23 and IL-12 in joint autoimmuneinflammation. J Exp Med. 2003; 198: 1951–7CrossRefGoogle Scholar
  5. 5.
    Blauvelt A et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator—controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017; 76: 405–17CrossRefGoogle Scholar
  6. 6.
    Reich K et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017; 76: 418–31CrossRefGoogle Scholar
  7. 7.
    Feagan B: Efficacy and safety of open-label maintenance therapy with subcutaneous risankizumab in patients with moderateto- severe crohn’s disease. Präsentiert auf der 25. UEG-Week, 29. Oktober bis 1. November 2017, Barcelona, SpanienGoogle Scholar
  8. 8.
    Langley RG et al. Secukinumab in plaque psoriasis — results of two phase 3 trials. N Engl J Med. 2014; 371: 326–38CrossRefGoogle Scholar
  9. 9.
    Griffiths CE et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386: 541–51CrossRefGoogle Scholar
  10. 10.
    Lebwohl M et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015; 373: 1318–28CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Dermatologikum HamburgHamburgDeutschland

Personalised recommendations